AlgoDx, a leading medical AI company, has announced that its sepsis detection software, NAVOY CDS®, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance marks a significant step in the company’s expansion into the U.S. market.

NAVOY CDS® is a software as a medical device (SaMD) designed to support clinicians in detecting sepsis among hospitalized patients, including those in emergency departments.

The software analyzes routinely collected vital signs to provide early warnings of sepsis, enabling timely medical interventions.

The FDA clearance highlights AlgoDx’s commitment to advancing medical technology. The software is expected to enhance patient care by facilitating earlier detection and treatment of sepsis.

Sepsis is a leading cause of in-hospital mortality worldwide, responsible for approximately 35% of hospital deaths. It results from an extreme immune response to infection, which can lead to organ failure and death.

Early detection and intervention are essential for improving survival rates. AlgoDx’s technology aims to improve sepsis management by providing healthcare providers with a tool to identify at-risk patients in various hospital settings.




Source: algodx.com

Report Abuse